Roche announced a major milestone at EASD 2025 conference: the integration of its Accu-Chek SmartGuide continuous glucose monitor (CGM) into the mySugr app. This update brings predictive glucose insights and therapy data into one platform, giving people with diabetes a more complete view of their health. The Accu-Chek SmartGuide, first launched in 2024, is Roche’s latest CGM solution for adults with type 1 or type 2 diabetes on insulin therapy.

The system features a water-resistant sensor worn for up to 14 days, delivering real-time glucose readings every five minutes. Clinical evaluations demonstrated an accuracy of 9.2% MARD and nearly all readings within safe ranges. Built-in AI algorithms analyze these values to predict future glucose patterns, allowing users to act before complications arise.

The SmartGuide CGM offers three layers of predictive support: it can indicate hypoglycemia risk within the next 30 minutes, forecast likely glucose changes for up to two hours, and estimate the risk of nocturnal hypoglycemia overnight. Since nighttime lows are among the biggest concerns for people with diabetes, these alerts aim to reduce anxiety, support better sleep, and give users and caregivers greater peace of mind.

With the new integration, these insights connect directly to mySugr, Roche’s digital diabetes management app with more than six million users worldwide. The app is designed to simplify daily care through a personalized logging screen, analytics that highlight glucose trends, and easy-to-share data reports for families, caregivers, and healthcare providers. By combining SmartGuide’s predictive technology with mySugr’s user-friendly tools, Roche offers people with diabetes a single hub for both real-time monitoring and long-term management.

The Accu-Chek SmartGuide has CE Mark and is available in 13 European countries. Roche plans to expand to over 30 global markets by the end of 2025. The mySugr integration will begin rolling out later this year in select regions, with broader access expected as regulatory approvals progress. To learn more about the Accu-Chek SmartGuide CGM and see how it works, check out the video below.

Disclaimer: Diabetech content is not medical advice—it’s for educational purposes only. Always consult with a physician before making changes to your healthcare.